Background Liver disease is an important complication in CF. Aims To determine if CFLD is
a risk factor for mortality in CF, and which baseline characteristics predict all-cause mortality …

Cystic fibrosis (CF) remains the most common indication for lung transplantation in children
and the third most common in adults and has the highest median survival posttransplant for …

Background Nodular liver (NOD) in cystic fibrosis (CF) suggests advanced CF liver disease
(aCFLD); little is known about progression of liver disease (LD) after detection of …

Background There are limited studies to date on the effects of elexacaftor/tezacaftor/ivacaftor
(E/T/I) on markers of liver fibrosis in adults with cystic fibrosis (CF). This study aims to …

Background Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver
disease, but objective parameters for its effect are lacking. Methods We used liver stiffness …

Cystic fibrosis-liver disease (CFLD) is one of the most common non-pulmonary
complications in the CF population, is associated with significant morbidity and represents …

The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other
physicochemical characteristics of the GI tract, and perturbations such as antibiotic …

Background Our understanding of the natural history of cystic fibrosis liver disease (CFLD) is
limited, leading to uncertainty for patients their families and clinicians when liver …

Approximately 5%‐10% of patients with cystic fibrosis (CF) will develop advanced liver
disease with portal hypertension, representing the third leading cause of death among …

Cystic fibrosis liver disease in the post-modulator era : Current Opinion in Pulmonary Medicine
Cystic fibrosis liver disease in the post-modulator era : Current Opinion in Pulmonary Medicine …